补益肺肾汤加减联合异丙托溴铵治疗慢性阻塞性肺疾病稳定期效果观察

Effect Observation on Treatment of Chronic Obstructive Pulmonary Disease during Stable Period with Buyifeishen Decotion Addition and Subraction Combined with Tiotropium Bromide

目的观察补益肺肾汤加减联合异丙托溴铵治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期的效果。方法选择2013年9月—2014年11月在我院住院和门诊就诊的COPD稳定期58例,随机将其分为观察组和对照组两组各29例,观察组采用补益肺肾汤加减联合异丙托溴铵治疗,对照组采用异丙托溴铵治疗,观察比较治疗前、后及治疗结束后1个月两组肺功能[第1秒钟用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)]、呼吸困难程度评分及生活质量评分。结果治疗后和治疗结束后1个月观察组肺功能指标FEV1、FEV1/FVC、呼吸困难评分及呼吸症状评分、活动能力评分、疾病影响评分、总评分均较治疗前改善,差异均具有统计学意义(P<0.05)。治疗后对照组肺功能指标FEV1/FVC及呼吸症状评分、疾病影响评分、总评分较治疗前改善,治疗结束后1个月对照组肺功能指标FEV1、FEV1/FVC及疾病影响评分、总评分较治疗前改善,差异均有统计学意义(P<0.05)。治疗后观察组肺功能指标FEV1、活动能力及疾病影响评分改善优于对照组,差异有统计学意义(P<0.05)。治疗结束后1个月观察组呼吸症状及疾病影响评分优于对照组,差异有统计学意义(P<0.05)。结论补益肺肾汤加减联合异丙托溴铵可以改善COPD稳定期患者的临床症状和体征,提高生活质量。

Objective To investigate the effects of Buyifeishen Decoction addition and subraction combined with Ipratropium Bromide in treatment of the chronic obstructive pulmonary disease during the stable period. Methods 58 cases were randomly assigned for control group（ 29 cases） and treatment group（ 29 cases） who were inpatients and outpatients with chronic obstructive pulmonary disease in the stable period admitted to our hospital between September 2013 and November 2014.The patients in control group were treated with Ipratropium Bromide,and the treatment group was given Buyifeishen decotion addition and subraction combined with Ipratropium Bromide. Lung function（ FEV1,FEV1 / FVC）,the dyspnea score,and the St. George＇s Respiratory Questionnaire（ SGRQ） scores of the 2 groups were recorded,analyzed and compared before treatment,after treatment and 1 month after the end of treatment. Results Compared with that before treatment,the pulmonary function indexes（ FEV1,FEV1 / FVC）,dyspnea score,respiratory symptom score,activity ability score,disease impact score,and total scores in the treatment group were significantly improved at the late stage of treatment and 1 month after the end of treatment in the treatment group（ P 0. 05）. In control group,pulmonary function index（ FEV1,FEV1 / FVC）,respiratory symptom score,disease impact score,and total scores were improved compared with that before treatment and after treatment; one month after the end of treatment,pulmonary function index（ FEV1,FEV1 / FVC）,disease impact score,and total scores were improved compared with that before treatment（ P 0. 05）. The lung function（ FEV1）,activity ability score and disease impact score in the treatment group were better than those in the control group after treatment（ P 0. 05）. One month after the end of treatment,the respiratory symptoms score and the disease impact score improvement in the treatment group were better than that in the control group（ P 0. 05）. Conclusion Buyifeishen Decoction addition and subtraction combined with Ipratropium Bromide in treatment of stable chronic obstructive pulmonary during the stable phase can improve the clinical symptoms,physical signs and the quality of life of the patients.